Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy. 

Accept / Decline

Technically we develop medicines. Practically we improve conditions for patients.

Ferring's R&D activities are always driven by the same goals: to develop patient-friendly products that treat unmet medical needs in our key therapeutic areas. We focus our R&D efforts on peptide-based drugs and biotechnology derived medicines.
Later stage small chemical molecules within our core therapeutic areas are also included in our development portfolio.
Investment in development includes the incorporation of state-of-the-art technology to capitalise on the company’s expertise.
We also strive to develop drug delivery systems that ensure convenient and efficient administration of our drugs.

  • Reproductive Medicine & Maternal Health
    Reproductive Medicine & Maternal Health

  • Reproductive Medicine & Maternal Health

    Ferring is a world leader in Assisted Reproductive Technology (ART) for fertility treatment. Ferring’s on-going research efforts in this area strive to meet the growing needs of patients as increasing numbers of couples seek help to conceive. Ferring also offers a range of peptide-based medicines to prevent pre-term labour.

  • Urology

  • Urology

    Ferring is committed to the development of medicines to treat urological disorders such as diabetes insipidus, enuresis and nocturia.

  • Endocrinology

  • Endocrinology

    Ferring produces a recombinant human growth hormone to treat growth failure in children and Turner's syndrome in girls.

Ferring Private Ltd.
168 Robinson Road
#13-01 Capital Tower  
068912 Singapore

Tel: +65 6812 7500
Fax: +65 6812 7510